

# Matthias Holdhoff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3968688/publications.pdf>

Version: 2024-02-01

89  
papers

12,689  
citations

136950

32  
h-index

62596

80  
g-index

92  
all docs

92  
docs citations

92  
times ranked

22787  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945
2	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
3	Frequent <i>ATR</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	1.8	532
4	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	7.1	317
5	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	27.8	276
6	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	4.9	253
7	First-in-Human Dose Study of the Novel Transforming Growth Factor- $\beta$ Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	7.0	199
8	Ivosidenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	1.6	167
9	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160
10	Systemic use of tumor necrosis factor alpha as an anticancer agent. <i>Oncotarget</i> , 2011, 2, 739-751.	1.8	151
11	High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. <i>Neurology</i> , 2014, 83, 235-239.	1.1	120
12	Central Nervous System Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1114-1151.	4.9	104
13	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561.	7.0	104
14	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- $\beta$ receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 357-370.	2.6	90
15	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1191-1202.	4.9	89
16	Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1284-1285.	6.3	79
17	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	5.2	77
18	Central Nervous System Cancers, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1517-1523.	4.9	69

#	ARTICLE	IF	CITATIONS
19	Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 143, 87-93.	2.9	68
20	Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 34, 181-185.	1.4	67
21	Determination of Î±-1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with ST1571. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 28, 75-85.	1.4	52
22	Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> Hybridization. <i>Clinical Cancer Research</i> , 2017, 23, 3150-3157.	7.0	52
23	Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2017, 42, e433-e435.	1.3	49
24	Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2010, 97, 241-245.	2.9	46
25	Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis. <i>Clinical Cancer Research</i> , 2011, 17, 3551-3557.	7.0	42
26	Actionable Molecular Biomarkers in Primary Brain Tumors. <i>Trends in Cancer</i> , 2016, 2, 338-349.	7.4	41
27	Ipilimumab-Induced Enteritis without Colitis: A New Challenge. <i>Case Reports in Oncology</i> , 2017, 9, 705-713.	0.7	41
28	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. <i>Oncotarget</i> , 2011, 2, 59-68.	1.8	40
29	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 845-852.	1.2	39
30	Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 123-127.	2.9	38
31	Controversies in the Adjuvant Therapy of High-Grade Gliomas. <i>Oncologist</i> , 2011, 16, 351-358.	3.7	37
32	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
33	Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 124, 307-316.	2.9	36
34	Blood-based biomarkers for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 113, 345-352.	2.9	35
35	Evolving Treatments for Primary Central Nervous System Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 454-466.	3.8	35
36	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33

#	ARTICLE	IF	CITATIONS
37	Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1571-1578.	4.9	31
38	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 279-285.	2.9	29
39	Validation of the Coronary Artery Calcium Data and Reporting System (CAC-DRS): Dual importance of CAC score and CAC distribution from the Coronary Artery Calcium (CAC) consortium. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 12-17.	1.3	28
40	Repeatability of <sup>18</sup> F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 393-398.	5.0	27
41	The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 347-354.	2.9	25
42	Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1165-1173.	4.9	23
43	Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. <i>World Neurosurgery</i> , 2019, 126, e1436-e1448.	1.3	23
44	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	23
45	Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage. <i>Advances in Radiation Oncology</i> , 2018, 3, 582-590.	1.2	20
46	Evaluation of Eight Plasma Proteins as Candidate Blood-Based Biomarkers for Malignant Gliomas. <i>Cancer Investigation</i> , 2014, 32, 423-429.	1.3	19
47	Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 3-9.	0.9	17
48	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17
49	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. <i>Case Reports in Oncology</i> , 2020, 13, 508-514.	0.7	15
50	Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. <i>CNS Oncology</i> , 2015, 4, 393-398.	3.0	14
51	<p></p>Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8323-8335.	2.0	14
52	A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vda006.	0.7	14
53	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154.	0.7	13
54	Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome. <i>American Journal of Hematology</i> , 2003, 73, 249-255.	4.1	12

#	ARTICLE	IF	CITATIONS
55	Emerging methods for disease monitoring in malignant gliomas. <i>CNS Oncology</i> , 2013, 2, 511-522.	3.0	10
56	Steroid-responsive intracranial germinoma presenting as Holmesâ€™ tremor: Importance of a tissue diagnosis. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 911-913.	1.5	10
57	Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. <i>Diagnostic Pathology</i> , 2019, 14, 16.	2.0	10
58	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. <i>Clinical Epigenetics</i> , 2021, 13, 104.	4.1	10
59	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 642-645.	4.9	9
60	Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. <i>Journal of Neuro-Oncology</i> , 2009, 94, 297-297.	2.9	8
61	White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab. <i>Journal of Neuro-Oncology</i> , 2019, 145, 461-466.	2.9	8
62	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017, 8, 35523-35531.	1.8	8
63	Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2022, 8, 688-700.	1.8	8
64	IDHâ€™mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature. <i>Brain Pathology</i> , 2021, 31, e12959.	4.1	7
65	Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma. <i>Blood</i> , 2020, 136, 12-13.	1.4	7
66	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	7
67	â€™Elderlyâ€™ patients with newly diagnosed glioblastoma deserve optimal care. <i>Journal of Neuro-Oncology</i> , 2013, 113, 343-344.	2.9	6
68	Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2013, 114, 275-279.	2.9	4
69	A 60-Year-Old Indian Male With Altered Sensorium and Extensive Lymphoma of the Scalp. <i>Seminars in Oncology</i> , 2013, 40, e9-e21.	2.2	4
70	<i>Pneumocystis jirovecii</i> prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists. <i>Neuro-Oncology Practice</i> , 2019, 6, 321-326.	1.6	4
71	Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression. <i>Cancer Investigation</i> , 2019, 37, 67-72.	1.3	4
72	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	1.2	4

#	ARTICLE	IF	CITATIONS
73	Report of Canonical <i>BCR</i> - <i>ABL1</i> Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 1348-1353.	3.0	3
74	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. <i>Tomography</i> , 2020, 6, 60-64.	1.8	2
75	Persistent Positron Emission Tomography-Positive Liver Lesions After Successful Chemotherapy in Mediastinal Seminoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2482-2484.	1.6	1
76	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. <i>Neuro-Oncology</i> , 2018, 20, vi15-vi15.	1.2	1
77	Discovery of predictive biomarkers in malignant gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1089-1090.	1.2	1
78	ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE) Tj ETQq0 0 0 rgBT /Overlo Neuro-Oncology, 2019, 21, vi23-vi23.	1.2	1
79	Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2020, 7, 52-58.	1.6	1
80	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. <i>Clinical Chemistry</i> , 2021, 67, 1524-1533.	3.2	1
81	Case Series of Cancer Patients Treated With Galunisertib, a Transforming Growth Factor-Beta Receptor I Kinase Inhibitor in a First-in-Human Dose Study. <i>Journal of Medical Cases</i> , 2014, 5, 603-609.	0.7	1
82	Challenges in Supportive Care of Patients with Neoplastic Meningitis. <i>The Journal of Supportive Oncology</i> , 2012, 10, 55-56.	2.3	0
83	PATH-35. FREQUENCY AND CHARACTERISTICS OF H3K27M-MUTATION IN ADULTS WITH RADIOGRAPHICALLY-DETERMINED MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi166-vi166.	1.2	0
84	ACTR-63. PHASE I DOSE ESCALATION STUDY OF PROCASPASE ACTIVATING COMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi28.	1.2	0
85	Cerebellar Melanoneurons: An Overlooked and Potentially Important Cell Population. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 242-243.	1.7	0
86	Approach to the low-grade glioma patient. , 2021, , 136-152.		0
87	Glioblastoma in older adults. <i>Aging</i> , 2018, 10, 154-155.	3.1	0
88	Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS. <i>Blood</i> , 2019, 134, 2875-2875.	1.4	0
89	NIMG-55. A QUANTITATIVE ANALYSIS OF BRAIN VOLUME DYNAMICS IN PCNSL PATIENTS TREATED WITH HIGH-DOSE METHOTREXATE-BASED THERAPY. <i>Neuro-Oncology</i> , 2020, 22, ii160-ii160.	1.2	0